Last updated 8 days ago
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
360 patients around the world
Available in Argentina, Mexico, United States, Spain
Eli Lilly and Company
24Research sites
360Patients around the world
This study is for people with
Dermatitis
Atopic dermatitis
Requirements for the patient
To 17 Years
All Gender
Medical requirements
- Have a diagnosis of AD prior to screening as stated in the criteria by the American Academy of Dermatology for at least: 12 months s if participants are ≥6 years of age, and 6 months if participants are 6 months to <6 years of age. Have an EASI score ≥16 at the screening and baseline. Have an IGA score ≥3 (scale of 0 to 4) at the screening and baseline. Have ≥10% BSA of AD involvement at the screening and baseline.
- Are currently enrolled or have participated within the last 8 weeks in a clinical study involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.Treatment with the following prior to the baseline: An investigational drug within 8 weeks or less than 5 half-lives, whichever is longer. Dupilumab within 8 weeks. Note: The enrollment of participants with prior use of Dupilumab will be limited to <20%. Treatment with a topical investigational drug within 2 weeks prior to the baseline. Have received a Bacillus Calmette-Guerin vaccination or treatment within less than 4 weeks before randomization.
Sites
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Psoriahue Medicina Interdisciplinaria - CABA, Buenos Aires
Fundación Respirar
CONEXA Investigación Clínica S.A.
Fundación CIDEA - Buenos Aires
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Instituto de Neumonología y Dermatología Dr. Luna
Universidad Autónoma de Nuevo León, Hospital Universitario Dr. José Eleuterio González
Eukarya PharmaSite
Panamerican Clinical Research S.A. de C.V
StudyADorable-1
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Atopic dermatitis
Requirements
To 17 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05559359
